Adiponectin agonists that may in the not-too-distant future potentially be used for promoting metabolic health and perhaps treat diabetes and other obesity co-morbidities should clinical studies demonstrate efficacy were identified in 2013 (18). This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.